Clay co-founded Seagen in 1998 with a vision to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, he built a foundation based on a unique science-driven culture, successful drug discovery and development, and a passion for helping patients. Today, Seagen has three FDA-approved medicines and leads the field in antibody–drug conjugate (ADC) technology and development.

Year joined:

1998 as co-founder

Experience:

Bristol-Myers Squibb Pharmaceutical Research Institute

National Institutes of Health, National Cancert Institute

Awards:

University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences

Pacific Northwest Ernst & Young Entrepreneur of the Year

Dealmaker of the Year by the Puget Sound Business Journal

Publications/Patents:

Author on more than 70 publications

Holds 15 patents

Education:

Ph.D., Genetics, George Washington University

B.S., Zoology, University of Maryland

Boards:

Director, Ultragenyx Pharmaceutical

Director, Washington Roundtable

Felix J. Baker, Ph.D., has served as a Director of Seattle Genetics since July 2003 and as our lead independent director since February 2005. As a board member and investor in many successful biotechnology companies, Dr. Baker is able to draw on his experience and vision in investing in and building companies to add significant value to Board of Directors discussions and company strategy.

Recent experience:

  • Baker Bros. Advisors LP
    • Founder and Co-Managing Member (2000-present)

Other public company boards:

  • Alexion Pharmaceuticals, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Kodiak Sciences Inc.

Education:

  • B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school

David W. Gryska joined our Board of Directors in March 2005. He has years of experience as Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios, Inc., and Cardiac Pathways Corporation. He brings to the Board valuable and relevant experience as a senior financial executive at life sciences and biotechnology companies engaged in financings, global expansion and other strategic transactions. He also has extensive knowledge of accounting principles and financial reporting rules and regulations, tax compliance, and oversight of the financial reporting processes of several large, publicly-traded corporations, which assists Mr. Gryska in fulfilling his duties as chair of our Audit Committee.

Recent experience:

  • Incyte Corporation
    • Executive Vice President and Chief Financial Officer (2014-2018; retired)
  • Myrexis, Inc.
    • Chief Operating Officer and Interim Chief Executive Officer (2012)
  • Celgene Corporation
    • Senior Vice President and Chief Financial Officer (2006-2010)

 Other public company boards:

  •  PDL BioPharma, Inc.
  • Aerie Pharmaceuticals, Inc.

Education:

  • M.B.A. from Golden Gate University
  • B.A. in Accounting and Finance, Loyola University

Marc E. Lippman, M.D., has served as a Director of Seattle Genetics since June 2000. Dr. Lippman’s extensive experience in treating patients and conducting oncology research at the National Cancer Institute and at the medical schools of the University of Miami, the University of Michigan and Georgetown University provides an important patient perspective and focus on innovation in our development of targeted oncology therapies. Dr. Lippman has authored more than 400 peer-reviewed publications and one of the standard texts on breast cancer.

Recent experience:

  • Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center
    • Professor of Oncology (2018-present)
  • University of Miami Leonard M. Miller School of Medicine
    • Kathleen and Stanley Glaser Professor of Medicine and Chairman of the Department of Medicine (2017-2018)
    • Deputy Director of the Sylvester Comprehensive Cancer Center (2008-2017)

Education:

  • M.D. from Yale where he was elected to Alpha Omega Alpha
  • B.A., magna cum laude, Cornell

Ted W. Love, M.D., joined our Board of Directors in August 2020. Dr. Love has more than two decades of leadership and management experience in the pharmaceutical industry, in addition to prior experience as a practicing physician. This allows Dr. Love to bring both strong business expertise and knowledge of patient perspectives to our Board of Directors.

Recent experience:

  • Global Blood Therapeutics, Inc.
    • President and Chief Executive Officer (2014-present)
  • Onyx Pharmaceuticals, Inc.
    • Executive Vice President, Research and Development and Technical Operations (2010-2012)

Other public company boards:

  • Global Blood Therapeutics, Inc.
  • Royalty Pharma plc

Education:

  • M.D. from Yale Medical School
  • B.A. in Molecular Biology,  Haverford College

John A. Orwin joined the Seattle Genetics Board of Directors in January 2014. He has many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, including Atreca, Inc., Relypsa, Inc., Affymax, Inc., Genentech, Inc., and Johnson & Johnson. This gives him a strong understanding of the biotechnology industry and the challenges we must meet to continue developing and commercializing our product candidates.

Recent experience:

  • Atreca, Inc.
    • President and Chief Executive Officer (2018-present)
  • Relypsa, Inc., now an affiliate of Vifor Pharma AG
    • Chief Executive Officer (2013-2017)
  • Affymax, Inc.
    • Board member (2011-2014)
    • Chief Executive Officer (2011-2013)
    • President and Chief Operating Officer (2010-2011)
  • Genentech, Inc, now a member of the Roche Group
    • Vice President and then Senior Vice President of the BioOncology Business Unit (2005-2010)

Other public company boards:

  • Atreca, Inc.
  • Retrophin, Inc.

Alpna Seth, Ph.D. joined our Board of Directors in March 2018. Dr. Seth has over 20 years of global experience in the biotechnology industry. Having held a range of leadership roles around the globe, Dr. Seth brings a breadth of experience in drug development, commercial, international operations, and general management.

Recent experience:

  • Proneurotech Inc.
    • Chief Executive Officer and President (2019-present)
  • Vir Biotechnology, Inc.
    • Chief Operating Officer (2017-2019)
  • Biogen, Inc.
    • Senior Vice President and Global Head of the Biosimilars Global Business Unit (2014-2017)
    • Range of leadership roles in business development, drug development and commercial (1998-2014)

Other public company boards:

  • Bio-Techne Corporation

Education:

  • Ph.D. in Biochemistry and Molecular Biology, University of Massachusetts Medical School
    • Conducted her post-doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow
  • 2002 graduate of the Advanced Management Program at Harvard Business School

Nancy A. Simonian, M.D. joined our Board of Directors in March 2012. As a current and former senior executive of several other biotechnology companies, including Syros Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. and Biogen, Dr. Simonian possesses a strong understanding of the biotechnology industry and the development and commercialization of our product candidates. Her knowledge of late-stage product development, as former Chief Medical Officer of Millennium Pharmaceuticals, Inc., and her understanding of patient perspectives, as a medical doctor, bring important insights to our Board of Directors.

Recent experience:

  • Syros Pharmaceuticals, Inc.
    • Chief Executive Officer (2012-present)
  • Millennium Pharmaceuticals, Inc., an affiliate of The Takeda Oncology Company
    • Chief Medical Officer (2006-2011)

Other public company boards:

  • Evelo Biosciences
  • Syros Pharmaceuticals

Education:

  • M.D. from the University of Pennsylvania Medical School
  • B.A. in Biology from Princeton University

Daniel G. Welch has served as a Director since June 2007. Mr. Welch’s global commercial background and strong senior executive experience at a wide range of biotechnology companies, including previously serving as Chairman and Chief Executive Officer of two publicly-traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc. gives him insight into strategy and planning for a biopharmaceutical company that is valuable to our senior management and our Board of Directors.

Recent experience:

  • Sofinnova Ventures
    • Executive Partner (2015-2018; retired)
  • InterMune, Inc.
    • Chief Executive Officer and President (2003-2014)
    • Chairman of the Board (2007-2014)

Other public company boards:

  • Intercept Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board)

Education:

  • M.B.A. from the University of North Carolina
  • B.A. from the University of Miami